Will azacitidine for 7 days plus venetoclax/venetoclax for 28 days work?

Azacitidine (Azacitidine) is a drug used to treat acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It achieves its anti-tumor effect by inhibiting DNA methyltransferase, thereby reactivating silent tumor suppressor genes. Venetoclax is a BCL-2 inhibitor that can induce tumor cell apoptosis, especially showing good efficacy in certain types of leukemia and lymphoma.

In a treatment regimen that combines azacitidine with venetoclax, azacitidine is usually administered in a 7-day cycle, while venetoclax is administered in a 28-day cycle. This combined treatment strategy aims to improve the therapeutic effect through the synergy of two drugs with different mechanisms.

Azacitidine's 7-day dosing regimen provides an effective basis for enhancing the sensitivity of tumor cells to venetoclax by regulating gene expression and affecting the cell cycle. Venetoclax gradually reaches therapeutic concentrations over a 28-day cycle, allowing it to fully exert its apoptosis-inducing effect. Studies have shown that azacitidine can change the tumor microenvironment and make tumor cells more responsive to venetoclax, thus improving the overall efficacy of treatment. This treatment is particularly suitable for older patients with co-morbidities because azacitidine and venetoclax have relatively mild side effects and can be administered on an outpatient basis.

When using them in combination, attention should be paid to drug interactions and individual patient differences. The combination therapy of azacitidine and venetoclax has shown good safety and tolerability in clinical trials. Common adverse reactions include low blood cell counts and risk of infection. Patients need to receive regular blood monitoring during treatment. In addition, doctors will adjust the drug dosage according to the patient's specific condition to ensure the effectiveness and safety of the treatment.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018